The collaboration aims to ensure the development of infigratinib for children living with achondroplasia, and eventually for other skeletal dysplasias in Japan.
Will create more than 150 new highly skilled jobs to focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world.